VEGF-binding polypeptide
US6270993A · kind A · utility
57Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 1998 |
| Grant date | Aug 7, 2001 |
| Priority date | — |
| Expiry date | Jul 15, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An object of the present invention is to provide a low molecular weight VEGF inhibitor that can be utilized to treat diseases accompanying neovascularization, such as solid tumors. It was found that a polypeptide containing immunoglobulin-like domain 1 and immunoglobulin-like domain 2 but neither immunoglobulin-like main 6 nor immunoglobulin-like domain 7 of the extracellular domain of the VEGF receptor FLT possess VEGF inhibitory activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.